Floatz logo

FLUOROURACILUM

Gallbladder Cancer

Lisata Therapeutics, Inc.Small moleculePhase 2Active
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
59/ 100
Competitive Position
95/ 100

Competitive context

29 Active assets in the Gallbladder Cancer cohort.

Asset / SponsorPhaseRating
Capecitabine
Merck Sharp & Dohme LLC
Phase 3BB
Eloxatin
Tianjin Medical University Cancer Institute and Hospital
Phase 3BB
Docetaxel
Merck Sharp & Dohme LLC
Phase 2BB
Sevoflurane
Tokyo Medical and Dental University
Phase 4BB
Epirubicin
Merck Sharp & Dohme LLC
Phase 2BB

View all 50 →

Same molecule, other indications

FLUOROURACILUM is also rated in:

colon carcinomaDormant
A
Indicative ·
82 / 100
View asset →
Unresectable or Metastatic Colorectal CancerDormant
BBB
Indicative ·
79 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →